Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRAF V600
i
Other names:
BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
673
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
HER-2 amplification + RAS wild-type + BRAF wild-type (9)
BRAF V600K + LDH elevation (3)
BRAF V600E + MSI-H (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)
BRAF V600E + ROS1 fusion (2)
BRAF mutation + MET amplification (2)
BRAF mutation + MSI-L/dMMR (2)
BRAF mutation + TERT overexpression (2)
BRAF wild-type + HER-2 positive (2)
EZR overexpression + BRAF V600E (2)
IDH1 mutation + BRAF V600E (2)
IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)
IDH2 mutation + BRAF V600E (2)
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)
MSI-H/dMMR + BRAF V600E (2)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
PD-L1 overexpression + BRAF V600E (2)
RAS wild-type + BRAF wild-type + HER-2 positive (2)
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)
ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)
BRAF E501Q + PD-L1 negative (1)
BRAF V600 + LDH elevation (1)
BRAF V600 + LDH elevation + PD-L1 negative (1)
BRAF V600E + CDKN2A deletion + MYCN amplification (1)
BRAF V600E + CDKN2A deletion + RB1 expression (1)
BRAF V600E + EGFR expression (1)
BRAF V600E + PTEN deletion (1)
BRAF V600E + SOX2 amplification (1)
BRAF V600K + CDKN2A deletion + RB1 expression (1)
BRAF mutation + PD-L1 overexpression (1)
BRAF mutation + TMB-H (1)
BRAF mutation + TMB-L + MSI-L/dMMR (1)
BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion (1)
BRAF wild-type + HGF elevation (1)
CD8 elevation + BRAF V600 (1)
Chr t(11;14) + BRAF mutation (1)
EGFR exon 19 deletion + BRAF G464A (1)
EGFR overexpression + BRAF V600E (1)
EGFR overexpression + BRAF mutation (1)
HER-2 amplification + BRAF wild-type (1)
HR positive + BRAF V600E (1)
KIAA1549-BRAF fusion + MET amplification (1)
KIAA1549-BRAF fusion + PTEN deletion (1)
KRAS wild-type + BRAF V600E (1)
LDH elevation + BRAF mutation (1)
MAP2K1 mutation + BRAF wild-type (1)
MSI-H/dMMR + BRAF Mutation (1)
MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)
NRAS mutation + BRAF wild-type (1)
PD-L1 expression + BRAF negative (1)
PIK3CA mutation + BRAF wild-type (1)
SEMA6A overexpression + BRAF mutation (1)
SRC overexpression + BRAF V600E (1)
TNFAIP3 overexpression + BRAF mutation (1)
PD-L1 overexpression + BRAF mutation (0)
HER-2 amplification + RAS wild-type + BRAF wild-type (9)
BRAF V600K + LDH elevation (3)
BRAF V600E + MSI-H (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)
BRAF V600E + ROS1 fusion (2)
BRAF mutation + MET amplification (2)
BRAF mutation + MSI-L/dMMR (2)
BRAF mutation + TERT overexpression (2)
BRAF wild-type + HER-2 positive (2)
EZR overexpression + BRAF V600E (2)
IDH1 mutation + BRAF V600E (2)
IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)
IDH2 mutation + BRAF V600E (2)
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)
MSI-H/dMMR + BRAF V600E (2)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
PD-L1 overexpression + BRAF V600E (2)
RAS wild-type + BRAF wild-type + HER-2 positive (2)
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)
ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)
BRAF E501Q + PD-L1 negative (1)
BRAF V600 + LDH elevation (1)
BRAF V600 + LDH elevation + PD-L1 negative (1)
BRAF V600E + CDKN2A deletion + MYCN amplification (1)
BRAF V600E + CDKN2A deletion + RB1 expression (1)
BRAF V600E + EGFR expression (1)
BRAF V600E + PTEN deletion (1)
BRAF V600E + SOX2 amplification (1)
BRAF V600K + CDKN2A deletion + RB1 expression (1)
BRAF mutation + PD-L1 overexpression (1)
BRAF mutation + TMB-H (1)
BRAF mutation + TMB-L + MSI-L/dMMR (1)
BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion (1)
BRAF wild-type + HGF elevation (1)
CD8 elevation + BRAF V600 (1)
Chr t(11;14) + BRAF mutation (1)
EGFR exon 19 deletion + BRAF G464A (1)
EGFR overexpression + BRAF V600E (1)
EGFR overexpression + BRAF mutation (1)
HER-2 amplification + BRAF wild-type (1)
HR positive + BRAF V600E (1)
KIAA1549-BRAF fusion + MET amplification (1)
KIAA1549-BRAF fusion + PTEN deletion (1)
KRAS wild-type + BRAF V600E (1)
LDH elevation + BRAF mutation (1)
MAP2K1 mutation + BRAF wild-type (1)
MSI-H/dMMR + BRAF Mutation (1)
MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)
NRAS mutation + BRAF wild-type (1)
PD-L1 expression + BRAF negative (1)
PIK3CA mutation + BRAF wild-type (1)
SEMA6A overexpression + BRAF mutation (1)
SRC overexpression + BRAF V600E (1)
TNFAIP3 overexpression + BRAF mutation (1)
PD-L1 overexpression + BRAF mutation (0)
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® CDx (110)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF V600
Melanoma
BRAF V600
Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
BRAF V600
Non Small Cell Lung Cancer
BRAF V600
Non Small Cell Lung Cancer
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
BRAF V600
Glioma
BRAF V600
Glioma
tovorafenib
Sensitive: A1 - Approval
tovorafenib
Sensitive
:
A1
tovorafenib
Sensitive: A1 - Approval
tovorafenib
Sensitive
:
A1
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
trametinib
Resistant: A2 - Guideline
trametinib
Resistant
:
A2
trametinib
Resistant: A2 - Guideline
trametinib
Resistant
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: A2 - Guideline
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A2
atezolizumab + vemurafenib + cobimetinib
Sensitive: A2 - Guideline
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
BRAF V600
Melanoma
BRAF V600
Melanoma
BRAF inhibitor + MEK inhibitor
Sensitive: A2 - Guideline
BRAF inhibitor + MEK inhibitor
Sensitive
:
A2
BRAF inhibitor + MEK inhibitor
Sensitive: A2 - Guideline
BRAF inhibitor + MEK inhibitor
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
pembrolizumab + dabrafenib
Sensitive: A2 - Guideline
pembrolizumab + dabrafenib
Sensitive
:
A2
pembrolizumab + dabrafenib
Sensitive: A2 - Guideline
pembrolizumab + dabrafenib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
pembrolizumab + trametinib
Sensitive: A2 - Guideline
pembrolizumab + trametinib
Sensitive
:
A2
pembrolizumab + trametinib
Sensitive: A2 - Guideline
pembrolizumab + trametinib
Sensitive
:
A2
BRAF V600
Rectal Cancer
BRAF V600
Rectal Cancer
cetuximab + encorafenib
Sensitive: A2 - Guideline
cetuximab + encorafenib
Sensitive
:
A2
cetuximab + encorafenib
Sensitive: A2 - Guideline
cetuximab + encorafenib
Sensitive
:
A2
BRAF V600
Rectal Cancer
BRAF V600
Rectal Cancer
panitumumab + encorafenib
Sensitive: A2 - Guideline
panitumumab + encorafenib
Sensitive
:
A2
panitumumab + encorafenib
Sensitive: A2 - Guideline
panitumumab + encorafenib
Sensitive
:
A2
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib + dabrafenib + PDR001
Sensitive: B - Late Trials
trametinib + dabrafenib + PDR001
Sensitive
:
B
trametinib + dabrafenib + PDR001
Sensitive: B - Late Trials
trametinib + dabrafenib + PDR001
Sensitive
:
B
BRAF V600
Melanoma
BRAF V600
Melanoma
nivolumab + ipilimumab
Sensitive: B - Late Trials
nivolumab + ipilimumab
Sensitive
:
B
nivolumab + ipilimumab
Sensitive: B - Late Trials
nivolumab + ipilimumab
Sensitive
:
B
BRAF V600
Melanoma
BRAF V600
Melanoma
PD1 inhibitor
Sensitive: B - Late Trials
PD1 inhibitor
Sensitive
:
B
PD1 inhibitor
Sensitive: B - Late Trials
PD1 inhibitor
Sensitive
:
B
BRAF V600
Thyroid Gland Carcinoma
BRAF V600
Thyroid Gland Carcinoma
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
BRAF V600
Ocular Melanoma
BRAF V600
Ocular Melanoma
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
BRAF V600
Ocular Melanoma
BRAF V600
Ocular Melanoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
trametinib + dabrafenib
Sensitive
:
C1
trametinib + dabrafenib
Sensitive: C1 - Off-label
trametinib + dabrafenib
Sensitive
:
C1
BRAF V600
Multiple Myeloma
BRAF V600
Multiple Myeloma
binimetinib + encorafenib
Sensitive: C1 - Off-label
binimetinib + encorafenib
Sensitive
:
C1
binimetinib + encorafenib
Sensitive: C1 - Off-label
binimetinib + encorafenib
Sensitive
:
C1
BRAF V600
Colorectal Cancer
BRAF V600
Colorectal Cancer
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
BRAF V600
Cholangiocarcinoma
BRAF V600
Cholangiocarcinoma
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
BRAF V600
Ganglioglioma
BRAF V600
Ganglioglioma
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login